|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000081818 |
Summary for PCDHB4 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000081818 | Gene symbol | PCDHB4 |
| Gene name | protocadherin beta 4 | |
| HGNC | 8689 | |
| Entrez ID | 56131 | |
| Gene type | protein_coding | |
| Synonyms | PCDHB4|PCDH-BETA4 | |
| UniProtAcc | Q9Y5E5 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for PCDHB4 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| PCDHB4 | 3.09e+02 | -1.12e+00 | 1.18e-01 | -9.44e+00 | 3.76e-21 | 1.33e-20 | BRCA |
Top |
Sex-biased somatic mutation for PCDHB4 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| TCGA-SKCM |
 |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
| ENSG00000081818 | SKCM | PCDHB4 | 18 | 5 | 4.83e-02 | 2.87e+00 | 1.01e+01 | 9.96e-01 | 6.25e-01 |
Top |
DNA methylation with beta values for PCDHB4 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LGG | cg17288142 | chr5:141121869 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 5.10e-01 | 6.22e-01 | 5.21e+00 | 1.89e-07 | 9.97e-07 | -1.12e-01 |
| THCA | cg13288164 | chr5:141121798 | CGI:chr5:141123308-141124222 | promoter | 6.01e-01 | 7.46e-01 | 5.88e+00 | 4.10e-09 | 2.04e-08 | -1.44e-01 |
| THCA | cg06048354 | chr5:141122230 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 3.37e-01 | 4.39e-01 | -3.10e+00 | 1.91e-03 | 6.18e-03 | -1.03e-01 |
| LAML | cg17288142 | chr5:141121869 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 3.30e-01 | 4.43e-01 | -2.24e+00 | 2.51e-02 | 3.79e-02 | -1.13e-01 |
| LAML | cg06048354 | chr5:141122230 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 4.43e-01 | 5.91e-01 | -2.29e+00 | 2.18e-02 | 3.52e-02 | -1.49e-01 |
| THYM | cg06048354 | chr5:141122230 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 6.23e-01 | 4.72e-01 | 4.03e+00 | 5.53e-05 | 1.72e-04 | 1.51e-01 |
| MESO | cg12990410 | chr5:141121535 | CGI:chr5:141123308-141124222 | promoter | 5.71e-01 | 7.47e-01 | -2.61e+00 | 9.01e-03 | 2.65e-02 | -1.76e-01 |
| MESO | cg03340754 | chr5:141122079 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 5.58e-01 | 6.67e-01 | -2.66e+00 | 7.88e-03 | 2.46e-02 | -1.08e-01 |
| DLBC | cg17288142 | chr5:141121869 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 7.72e-01 | 5.84e-01 | 2.86e+00 | 4.30e-03 | 1.21e-02 | 1.88e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg13288164 | chr5:141121798 | CGI:chr5:141123308-141124222 | promoter | 7.96e-01 | 4.05e-01 | -2.01e+00 | 4.40e-02 | 4.46e-02 | 3.91e-01 |
| KIRC | cg06048354 | chr5:141122230 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 4.91e-01 | 3.09e-01 | 3.76e+00 | 1.73e-04 | 3.30e-04 | 1.82e-01 |
| HNSC | cg24818200 | chr5:141121783 | CGI:chr5:141123308-141124222 | promoter | 8.28e-01 | 7.11e-01 | 2.05e+00 | 4.00e-02 | 4.14e-02 | 1.17e-01 |
| HNSC | cg03340754 | chr5:141122079 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 5.91e-01 | 4.84e-01 | 2.71e+00 | 6.82e-03 | 9.26e-03 | 1.08e-01 |
| LUSC | cg07129523 | chr5:141121821 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 3.21e-01 | 7.55e-02 | 3.98e+00 | 6.89e-05 | 6.07e-04 | 2.46e-01 |
| LUSC | cg17288142 | chr5:141121869 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 2.96e-01 | 1.09e-01 | 3.67e+00 | 2.43e-04 | 1.08e-03 | 1.87e-01 |
| LUSC | cg24918705 | chr5:141121739 | CGI:chr5:141123308-141124222 | promoter | 2.68e-01 | 8.47e-02 | 3.96e+00 | 7.60e-05 | 6.28e-04 | 1.83e-01 |
| LUSC | cg03340754 | chr5:141122079 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 5.58e-01 | 4.27e-01 | 2.33e+00 | 1.97e-02 | 2.36e-02 | 1.31e-01 |
| LUSC | cg06048354 | chr5:141122230 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 6.32e-01 | 4.14e-01 | 3.34e+00 | 8.39e-04 | 2.31e-03 | 2.19e-01 |
| BLCA | cg03340754 | chr5:141122079 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 5.70e-01 | 3.97e-01 | 2.75e+00 | 5.94e-03 | 9.34e-03 | 1.73e-01 |
| LIHC | cg13925975 | chr5:141122542 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 1.75e-01 | 2.81e-01 | -5.68e+00 | 1.35e-08 | 1.01e-07 | -1.06e-01 |
| KIRP | cg12990410 | chr5:141121535 | CGI:chr5:141123308-141124222 | promoter | 7.19e-01 | 5.59e-01 | 4.31e+00 | 1.63e-05 | 5.61e-05 | 1.60e-01 |
| ESCA | cg07129523 | chr5:141121821 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 4.65e-01 | 1.85e-01 | 2.07e+00 | 3.80e-02 | 4.61e-02 | 2.79e-01 |
| ESCA | cg17288142 | chr5:141121869 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 3.91e-01 | 1.57e-01 | 2.22e+00 | 2.62e-02 | 4.25e-02 | 2.34e-01 |
| CHOL | cg07129523 | chr5:141121821 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 4.84e-01 | 7.24e-02 | 2.06e+00 | 3.90e-02 | 4.26e-02 | 4.12e-01 |
| CHOL | cg24918705 | chr5:141121739 | CGI:chr5:141123308-141124222 | promoter | 2.51e-01 | 8.06e-02 | 2.51e+00 | 1.22e-02 | 2.39e-02 | 1.70e-01 |
| CHOL | cg15044767 | chr5:141122202 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 4.72e-01 | 2.86e-01 | 2.43e+00 | 1.50e-02 | 2.65e-02 | 1.87e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg07129523 | chr5:141121821 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 3.21e-01 | 9.04e-02 | 9.85e+00 | 6.87e-23 | 4.79e-22 | 2.30e-01 |
| BRCA | cg17288142 | chr5:141121869 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 3.73e-01 | 1.05e-01 | 1.02e+01 | 1.57e-24 | 1.28e-23 | 2.68e-01 |
| BRCA | cg24918705 | chr5:141121739 | CGI:chr5:141123308-141124222 | promoter | 2.42e-01 | 1.04e-01 | 8.67e+00 | 4.33e-18 | 2.01e-17 | 1.38e-01 |
| BRCA | cg03340754 | chr5:141122079 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 5.54e-01 | 3.82e-01 | 5.34e+00 | 9.17e-08 | 1.88e-07 | 1.73e-01 |
| BRCA | cg15044767 | chr5:141122202 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 4.44e-01 | 3.25e-01 | 6.28e+00 | 3.38e-10 | 8.52e-10 | 1.19e-01 |
| BRCA | cg06048354 | chr5:141122230 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 5.58e-01 | 3.17e-01 | 3.07e+00 | 2.13e-03 | 2.67e-03 | 2.42e-01 |
| THCA | cg13288164 | chr5:141121798 | CGI:chr5:141123308-141124222 | promoter | 6.01e-01 | 4.55e-01 | 2.60e+00 | 9.44e-03 | 1.37e-02 | 1.47e-01 |
| LIHC | cg07129523 | chr5:141121821 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 1.73e-01 | 6.17e-02 | 4.78e+00 | 1.75e-06 | 1.96e-05 | 1.11e-01 |
| LIHC | cg24818200 | chr5:141121783 | CGI:chr5:141123308-141124222 | promoter | 6.40e-01 | 3.31e-01 | 3.60e+00 | 3.17e-04 | 9.27e-04 | 3.09e-01 |
| LIHC | cg03340754 | chr5:141122079 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 4.80e-01 | 3.54e-01 | 2.78e+00 | 5.45e-03 | 8.60e-03 | 1.25e-01 |
| KIRP | cg02462812 | chr5:141121953 | CGI:chr5:141123308-141124222 | UTR,promoter,exon,gene body | 7.72e-01 | 6.49e-01 | 2.77e+00 | 5.60e-03 | 1.15e-02 | 1.24e-01 |
| KIRP | cg15044767 | chr5:141122202 | CGI:chr5:141123308-141124222 | promoter,exon,CDS,gene body | 4.79e-01 | 3.33e-01 | 3.06e+00 | 2.25e-03 | 6.39e-03 | 1.46e-01 |
Top |
Exon skipping events with PSI in TCGA for PCDHB4 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for PCDHB4 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for PCDHB4 |
| TFs related to PCDHB4. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | ZNF418 | PCDHB4 | 5.67e+00 | 9.87e-01 | 4.91e+00 | 1.23e-02 | Male-biased |
| BLCA | DMRT3 | PCDHB4 | 7.29e+00 | 9.94e-01 | 6.32e+00 | 5.74e-03 | Male-biased |
| BLCA | DMRTA1 | PCDHB4 | 7.16e+00 | 9.93e-01 | 6.26e+00 | 7.08e-03 | Male-biased |
| BLCA | DMRTA2 | PCDHB4 | 7.34e+00 | 9.93e-01 | 6.41e+00 | 6.44e-03 | Male-biased |
| BLCA | IRF2 | PCDHB4 | 6.46e+00 | 9.90e-01 | 5.64e+00 | 9.48e-03 | Male-biased |
| BLCA | IRF9 | PCDHB4 | 6.86e+00 | 9.92e-01 | 6.00e+00 | 8.09e-03 | Male-biased |
| BLCA | MYNN | PCDHB4 | 6.42e+00 | 9.96e-01 | 5.29e+00 | 3.46e-03 | Male-biased |
| BLCA | PRDM1 | PCDHB4 | 6.30e+00 | 9.95e-01 | 5.25e+00 | 4.39e-03 | Male-biased |
| BLCA | SKOR2 | PCDHB4 | 7.46e+00 | 9.92e-01 | 6.59e+00 | 7.98e-03 | Male-biased |
| BLCA | SOX14 | PCDHB4 | 7.07e+00 | 9.93e-01 | 6.16e+00 | 6.89e-03 | Male-biased |
| BLCA | SOX18 | PCDHB4 | 6.87e+00 | 9.94e-01 | 5.89e+00 | 5.40e-03 | Male-biased |
| BLCA | STAT2 | PCDHB4 | 5.42e+00 | 9.94e-01 | 4.34e+00 | 3.99e-03 | Male-biased |
| BLCA | UNCX | PCDHB4 | 7.31e+00 | 9.96e-01 | 6.24e+00 | 4.03e-03 | Male-biased |
| BLCA | ZNF132 | PCDHB4 | 3.99e+00 | 1.21e-02 | 4.80e+00 | 9.83e-01 | Female-biased |
| BLCA | ZNF334 | PCDHB4 | 6.42e+00 | 9.99e-01 | 4.85e+00 | 8.05e-04 | Male-biased |
| BLCA | ZNF354A | PCDHB4 | 7.11e+00 | 9.95e-01 | 6.06e+00 | 4.40e-03 | Male-biased |
| BLCA | ZNF418 | PCDHB4 | 5.79e+00 | 9.98e-01 | 4.12e+00 | 5.83e-04 | Male-biased |
| CHOL | MYNN | PCDHB4 | 5.61e+00 | 8.43e-03 | 6.60e+00 | 9.91e-01 | Female-biased |
| CHOL | STAT2 | PCDHB4 | 4.72e+00 | 1.56e-02 | 5.54e+00 | 9.83e-01 | Female-biased |
| CHOL | ZNF334 | PCDHB4 | 5.45e+00 | 1.89e-03 | 6.81e+00 | 9.98e-01 | Female-biased |
| CHOL | ZNF418 | PCDHB4 | 4.89e+00 | 1.05e-03 | 6.38e+00 | 9.98e-01 | Female-biased |
| GBM | PRDM6 | PCDHB4 | 4.40e+00 | 9.92e-01 | 2.49e+00 | 6.69e-04 | Male-biased |
| GBM | ZNF2 | PCDHB4 | 5.05e+00 | 5.50e-03 | 6.37e+00 | 9.94e-01 | Female-biased |
| GBM | ZNF235 | PCDHB4 | 4.37e+00 | 9.92e-01 | 1.90e+00 | 7.00e-05 | Male-biased |
| GBM | ZNF287 | PCDHB4 | 4.24e+00 | 9.89e-01 | 2.06e+00 | 2.34e-04 | Male-biased |
| GBM | ZNF334 | PCDHB4 | 5.85e+00 | 9.83e-01 | 4.89e+00 | 1.58e-02 | Male-biased |
| GBM | ZNF418 | PCDHB4 | 5.34e+00 | 9.98e-01 | 3.33e+00 | 5.03e-04 | Male-biased |
| GBM | ZNF98 | PCDHB4 | 4.51e+00 | 9.90e-01 | 3.08e+00 | 3.55e-03 | Male-biased |
| UVM | DMRT3 | PCDHB4 | 7.75e+00 | 9.99e-01 | 5.01e+00 | 3.63e-04 | Male-biased |
| UVM | DMRTA1 | PCDHB4 | 7.75e+00 | 1.00e+00 | 4.80e+00 | 1.88e-04 | Male-biased |
| UVM | DMRTA2 | PCDHB4 | 7.85e+00 | 1.00e+00 | 4.99e+00 | 2.51e-04 | Male-biased |
| UVM | IRF2 | PCDHB4 | 6.71e+00 | 9.97e-01 | 4.72e+00 | 2.51e-03 | Male-biased |
| UVM | IRF9 | PCDHB4 | 6.96e+00 | 9.95e-01 | 5.21e+00 | 4.34e-03 | Male-biased |
| UVM | MYNN | PCDHB4 | 6.89e+00 | 9.99e-01 | 3.78e+00 | 1.18e-04 | Male-biased |
| UVM | PRDM1 | PCDHB4 | 6.61e+00 | 9.99e-01 | 4.16e+00 | 8.09e-04 | Male-biased |
| UVM | PRDM6 | PCDHB4 | 5.74e+00 | 9.98e-01 | 2.47e+00 | 6.79e-05 | Male-biased |
| UVM | SKOR2 | PCDHB4 | 7.85e+00 | 9.99e-01 | 5.38e+00 | 7.71e-04 | Male-biased |
| UVM | SOX14 | PCDHB4 | 7.37e+00 | 9.98e-01 | 5.18e+00 | 1.56e-03 | Male-biased |
| UVM | SOX18 | PCDHB4 | 7.39e+00 | 9.99e-01 | 4.87e+00 | 6.74e-04 | Male-biased |
| UVM | STAT2 | PCDHB4 | 6.03e+00 | 9.99e-01 | 2.83e+00 | 8.43e-05 | Male-biased |
| UVM | UNCX | PCDHB4 | 7.64e+00 | 9.99e-01 | 5.10e+00 | 6.34e-04 | Male-biased |
| UVM | ZFP28 | PCDHB4 | 5.49e+00 | 9.96e-01 | 3.15e+00 | 9.99e-04 | Male-biased |
| UVM | ZNF132 | PCDHB4 | 3.12e+00 | 9.81e-05 | 6.29e+00 | 9.99e-01 | Female-biased |
| UVM | ZNF2 | PCDHB4 | 4.35e+00 | 2.25e-03 | 6.39e+00 | 9.97e-01 | Female-biased |
| UVM | ZNF235 | PCDHB4 | 5.76e+00 | 9.98e-01 | 2.14e+00 | 2.86e-05 | Male-biased |
| UVM | ZNF287 | PCDHB4 | 5.65e+00 | 9.98e-01 | 2.29e+00 | 5.46e-05 | Male-biased |
| UVM | ZNF334 | PCDHB4 | 7.33e+00 | 1.00e+00 | 2.54e+00 | 2.80e-06 | Male-biased |
| UVM | ZNF354A | PCDHB4 | 7.56e+00 | 1.00e+00 | 4.69e+00 | 2.45e-04 | Male-biased |
| UVM | ZNF418 | PCDHB4 | 7.17e+00 | 1.00e+00 | 1.14e+00 | 1.05e-07 | Male-biased |
| UVM | ZNF490 | PCDHB4 | 6.44e+00 | 9.86e-01 | 5.25e+00 | 1.33e-02 | Male-biased |
| UVM | ZNF98 | PCDHB4 | 5.72e+00 | 9.98e-01 | 2.81e+00 | 2.01e-04 | Male-biased |
| PCDHB4 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for PCDHB4 |
| RBPs related to ES in PCDHB4. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PCDHB4 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000081818 | AC022364.1,hsa-mir-340,PCDHB4 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000081818 | AC093010.2,hsa-mir-142,PCDHB4 | Male-specific ceRNA | TCGA-HNSC |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs755038 | chr5:133468420:C:G | - | 0.227087738283053 | 5.92159212908854e-05 | PAAD | Female-baised eQTL |
| rs6869347 | chr5:141429173:C:T | - | 0.225175110812602 | 8.69326019234784e-05 | PAAD | Female-baised eQTL |
| rs7710691 | chr5:141289456:T:C | - | 0.224281414517018 | 9.94771855424535e-05 | PAAD | Female-baised eQTL |
| rs3749778 | chr5:141351790:G:T | - | 0.224517373621933 | 0.000101446826194123 | PAAD | Female-baised eQTL |
| rs74814733 | chr5:141326712:A:G | - | 0.221333329487533 | 0.000164485913246141 | PAAD | Female-baised eQTL |
| rs79225545 | chr5:141342372:A:G | - | 0.221089642498207 | 0.000176943815712901 | PAAD | Female-baised eQTL |
| rs17166705 | chr5:133450110:A:G | - | 0.181033949330123 | 0.00238836169062566 | PAAD | Female-baised eQTL |
| rs12522557 | chr5:133468783:A:G | - | 0.17365426798065 | 0.00358429482958297 | PAAD | Female-baised eQTL |
| rs10040993 | chr5:141298601:C:A | - | 0.170925138287774 | 0.00520478430479881 | PAAD | Female-baised eQTL |
| rs10074100 | chr5:141298639:A:G | - | 0.170925138287774 | 0.00520478430479881 | PAAD | Female-baised eQTL |
| rs10051009 | chr5:141298734:G:C | - | 0.170925138287774 | 0.00520478430479881 | PAAD | Female-baised eQTL |
| rs10491308 | chr5:141298909:A:G | - | 0.170925138287774 | 0.00520478430479881 | PAAD | Female-baised eQTL |
| rs7714977 | chr5:141299581:G:C | - | 0.170925138287774 | 0.00520478430479881 | PAAD | Female-baised eQTL |
| rs7702064 | chr5:141299703:T:C | - | 0.170925138287774 | 0.00520478430479881 | PAAD | Female-baised eQTL |
| rs12521332 | chr5:133451212:T:G | - | 0.167596440400608 | 0.00787720542081446 | PAAD | Female-baised eQTL |
| rs79989136 | chr5:133458569:T:C | - | 0.167596440400608 | 0.00787720542081446 | PAAD | Female-baised eQTL |
| rs718410 | chr5:133471980:C:T | - | 0.167596440400608 | 0.00787720542081446 | PAAD | Female-baised eQTL |
| rs11951280 | chr5:133459932:A:G | - | 0.161482093529728 | 0.0101002818254583 | PAAD | Female-baised eQTL |
| rs12109059 | chr5:133466404:C:T | - | 0.159467025890473 | 0.0128602416931297 | PAAD | Female-baised eQTL |
| rs73283613 | chr5:133466512:G:A | - | 0.159467025890473 | 0.0128602416931297 | PAAD | Female-baised eQTL |
| rs923183 | chr5:145227119:A:G | - | 0.255673930494038 | 0.0193200534101167 | PAAD | Female-baised eQTL |
| rs17166704 | chr5:133449463:G:A | - | 0.150518011863597 | 0.0242216237541295 | PAAD | Female-baised eQTL |
| rs1499774 | chr5:136374453:C:G | - | 0.11666743072532 | 0.0278684672538895 | PAAD | Female-baised eQTL |
| rs66475428 | chr5:136386840:T:C | - | 0.11666743072532 | 0.0278684672538895 | PAAD | Female-baised eQTL |
| rs66464875 | chr5:136388826:C:A | - | 0.11666743072532 | 0.0278684672538895 | PAAD | Female-baised eQTL |
| rs6887707 | chr5:133451605:C:A | - | 0.144335729654253 | 0.0327721242649396 | PAAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs35704701 | chr5:135275933:C:T | - | 0.34198983907386 | 0.00246667382585996 | PCPG | Male-baised eQTL |
| rs10515469 | chr5:135276382:G:A | - | 0.31364814462325 | 0.00379101792409047 | PCPG | Male-baised eQTL |
| rs7702840 | chr5:148486319:T:G | - | 0.302004140235964 | 0.00617382964393028 | SARC | Male-baised eQTL |
| rs7722894 | chr5:141833087:C:T | - | 0.231936251971094 | 0.0176177813702423 | SARC | Male-baised eQTL |
| rs78120442 | chr5:137379571:C:T | - | 0.102955303949062 | 0.0382723852615602 | KIRC | Male-baised eQTL |
| rs10066872 | chr5:137380871:C:A | - | 0.102955303949062 | 0.0382723852615602 | KIRC | Male-baised eQTL |
| rs10067086 | chr5:137381212:C:T | - | 0.102955303949062 | 0.0382723852615602 | KIRC | Male-baised eQTL |
| rs10041855 | chr5:137381383:G:C | - | 0.102955303949062 | 0.0382723852615602 | KIRC | Male-baised eQTL |
| rs4620017 | chr5:137382572:T:C | - | 0.102955303949062 | 0.0382723852615602 | KIRC | Male-baised eQTL |
| rs10078812 | chr5:137382751:T:C | - | 0.102955303949062 | 0.0382723852615602 | KIRC | Male-baised eQTL |
| rs10055819 | chr5:137382793:A:C | - | 0.102955303949062 | 0.0382723852615602 | KIRC | Male-baised eQTL |
| rs9327788 | chr5:137383049:T:C | - | 0.102955303949062 | 0.0382723852615602 | KIRC | Male-baised eQTL |
| rs10073075 | chr5:137383733:C:T | - | 0.102912071574327 | 0.0383997876530947 | KIRC | Male-baised eQTL |
| rs13359529 | chr5:137377193:C:T | - | 0.102597586887781 | 0.0461374218243614 | KIRC | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000081818 |
| CpG Site: cg08626876 | |
| Position to Gene: gene,exon,promoter,UTR | |
| Male Effect: -0.436972665103951 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg08626876 | chr5:141121958 | gene,exon,promoter,UTR | -0.436972665103951 | 4.17807353540713e-06 | -0.39795431672549786 | 3.779035506446535e-08 | KIRP |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of PCDHB4 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
